Taken together, our findings suggest that SSCE might alleviate 3-NPA-induced striatal toxicity by inhibiting activation of the NF-κB pathway and that SSCE could be useful as a treatment for HD-like syndromes. Here, NFKB1 is linked to Huntington disease.